Cancer drug ixazomib tested as potential MS treatment
NCT ID NCT03783416
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This phase 1b trial is testing whether ixazomib, a drug already used for multiple myeloma, is safe for people with multiple sclerosis. The study will enroll 72 adults with relapsing-remitting or progressive MS. Participants will receive either ixazomib or a placebo for up to 24 months, and researchers will monitor side effects and look for changes in immune markers in the spinal fluid.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ixazomib (NINLARO)
What this could lead to
If it works, this could point toward a new way to control multiple sclerosis by targeting the immune cells that drive the disease.
What could go wrong
This is a very early phase 1b trial with only 72 people, so it is primarily checking safety. It may not show clear benefit, and ixazomib has known side effects from its use in cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal London Hospital, Barts Health NHS Foundation Trust
RECRUITINGLondon, Greater London, E1 1BB, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact